BIRKI (Boehringer Ingelheim Pharma/INSERM)

N/A

Report date: 2025/01/26 18:39:10
NME

Base Information

Drug NameBIRKI (Boehringer Ingelheim Pharma/INSERM)
Drug Alias NameROCK1/2 Inhibitor (Boehringer Ingelheim Pharma/INSERM)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRho-associated protein kinase 2 inhibitorsRho-associated protein kinase 1 inhibitors
TargetsRho-associated protein kinase 1Rho-associated protein kinase 2
Therapy Area/IndicationsDiabetic Retinopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim Pharma Gmbh & Co Kg
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Sante Et De La Recherche MedicaleBoehringer Ingelheim Pharma Gmbh & Co Kg
Inactive CompaniesN/A
Active IndicationsDiabetic Retinopathy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A